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Caspases are proteolytic enzymes that are essential for apoptosis.
Understanding the many discrete and interacting signaling path-
ways mediated by caspases requires the identification of the
natural substrate repertoire for each caspase of interest. Using an
amplification-based protein selection technique called mRNA dis-
play, we developed a high-throughput screen platform for caspase
family member specific substrates on a proteome-wide scale. A
large number of both known and previously uncharacterized
caspase-3 substrates were identified from the human proteome.
The proteolytic features of these selected substrates, including
their cleavage sites and specificities, were characterized. Sub-
strates that were cleaved only by caspase-8 or granzyme B but not
by caspase-3, were readily selected. The method can be widely
applied for efficient and systematic identification of the family
member specific natural substrate repertoire of any caspase in an
organism of interest, in addition to that of numerous other pro-
teases with high specificity.
in vitro protein selection  mRNA display  natural caspase substrate
repertoire  natural granzyme B substrates
Highly specific proteolysis of bioactive molecules is one of themost important mechanisms to achieve precise cellular control
of many essential biological processes. Thus far, 500 genes that
encode proteases or protease-like molecules have been annotated
in the human genome (1). One of the most vital biochemical
pathways that are mediated by proteases is apoptosis. Because
caspase activation is a crucial event in apoptosis, identification of
their downstream substrates on a proteome-wide scale is essential
to our understanding of the molecular mechanisms of programmed
cell death. Although a number of caspase substrates have been
identified, it appears that many more apoptotic caspase targets,
especially those caspase family member specific substrates, have not
yet been revealed (2–4). The identification of family member
specific substrates of each caspase on a proteome-wide scale,
however, is a major undertaking. This challenge is further compli-
cated by the overlapping substrate specificities of multiple caspase
family members.
Four global methods have been used to identify the downstream
substrates of caspases. The first method is a mass-spectrometric
approach that permits identification of the cleavage sites of rela-
tively abundant proteins under physiological conditions. However,
it appears that this method predominantly identified some classes
of substrates such as RNA-binding proteins (5). It is also difficult
to unambiguously attribute a particular cleavage event to a specific
caspase, because of the presence of multiple caspases and numerous
other proteases in cell lysate. The second method is the small pool
expression cloning strategy that has been successfully used to
identify several previously uncharacterized caspase and recently
granzyme B substrates (3, 6). It is time consuming to screen the
whole cDNA library by progressive subdivision and reexamination
of a large number of subpools each with hundreds of individual
clones. The third method is yeast two-hybrid approach that uses
inactive caspase mutants (7). This indirect binding rather than
cleavage method would result in preferential enrichment of sub-
strates that tightly bind to the caspase used in the screen. The fourth
approach is to use a synthetic peptide library that is appropriately
displayed, e.g., on phage, the bacterial cell membrane, or fluoro-
genic peptide microarrays. This approach has been successfully
used to determine the specificity of various proteases including
caspases (8, 9). However, the optimal consensus sequences identi-
fied from the short peptide libraries were poorly correlated with
naturally occurring protease substrates and are therefore less
biologically relevant. Identification of natural protease substrates by
using these display methods has not yet been demonstrated. In
general, these methods only permit the identification of a limited
number of caspase substrates.
To identify natural family member specific caspase substrates on
a proteome-wide scale, a systematic and broadly applicable strategy
is greatly desired. mRNA display is a technology that allows
covalent linkage between an RNA and its encoded protein (10–12).
Using an mRNA-displayed protein library, multiple rounds of
selection and amplification can be performed, enabling enrichment
of rare sequences with desired properties. Compared with other
peptide or protein selection methods, mRNA display has several
advantages. First, the stable linkage between mRNA and protein
makes it possible to use arbitrary selection conditions such as
sequential cleavage with a series of different caspases. Therefore, it
allows us to identify protein sequences that are cleaved only by the
caspase member of interest, but not by other members. Second,
protein libraries containing as many as 10121013 unique sequences
can be generated and selected, orders of magnitude higher than can
be achieved by using other methods. Therefore, both the likelihood
of isolating rare sequences and the diversity of sequences isolated
in a given selection are significantly increased. Using mRNA-
display-based protein selection, we identified and characterized a
large number of caspase-3 substrates, including 26 known and 89
previously uncharacterized downstream caspase-3 targets [support-
ing information (SI) Tables 2–4]. The cleavage sites on the selected
fragments from known caspase-3 substrates correlate very well with
those previously reported and the cleavage sites on the previously
uncharacterized substrates could be readily mapped. We also
demonstrated that downstream substrates that were cleaved only by
caspase-8 or granzyme B, but not by caspase-3, could be readily
selected. These results will contribute to deciphering the apoptotic
signaling pathways mediated by individual caspases or caspase-like
proteases.
Results and Discussion
Natural Proteome Domain Library Used in the Proteolytic Selection.
The natural proteome domain library used in the selection was
constructed with a mixture of Poly(A) mRNAs from human brain,
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heart, spleen, thymus, and muscle, as reported (12). Because the
initial library was preselected to remove out-of-frame sequences,
the percentage of the sequences in alternate frames was 3% and
1% before and after the proteolytic selection, respectively. For
most sequences, the length of the protein portion from the ORFs
of natural proteins was in the range of 80–200 aa. Protein domains
with this length are more likely than short synthetic peptides to
adopt native conformations or tertiary structures. Therefore, this
method makes it possible to identify other unknown residues or
structural motifs, in addition to the cleavage sites, which might play
an important role in protease substrate recognition. Typically, 1.5
pmol (1012 molecules) of mRNA-displayed protein sequences was
generated and used in the proteolytic selection. Therefore, each
protein and its fragments should be represented by numerous
copies in the library.
Selection Scheme for Efficient Enrichment of Substrates Cleaved by
the Caspase of Interest. To select caspase substrates from an
mRNA-displayed human proteome domain library, we immobi-
lized the proteome library on streptavidin-agarose beads through a
biotin residue that was efficiently and site-specifically introduced at
the N-terminal AviTag by using the BirA enzyme (13) (SI Fig. 6).
Consequently, only sequences specifically cleaved by the caspase of
interest were released and enriched. Several procedures were used
to minimize the enrichment of nonspecific sequences, as detailed in
Materials and Methods. Upon incubation with a purified caspase of
interest, cleaved protein sequences were released and enriched,
with the intact mRNAs still covalently attached to their C termini
(Fig. 1). To avoid overdigestion, we first tested the in vitro digestion
conditions for several well known caspase substrates, including
PARP-1, calpastatin, RAD21, hnRNP A2/B1, and Bid. The incu-
bation time and the amount of caspase used in the selection were
chosen to result in 50% cleavage of these known substrates. The
selected sequences were then amplified for sequencing or used as
templates for iterative rounds of selection.
SI Fig. 7 shows the selection profiles using caspase-3. In the first
two rounds, the amount of immobilized fusion molecules released
from the solid surface by caspase-3 was undetectable (0.1%). In
round 3, however, 1.5% of total immobilized radioactive counts
were recovered. By cloning and sequencing, it was found that 99%
of the selected sequences were in the correct reading frame as in the
natural proteins. The selected sequences were diverse, although
fragments from some genes had more copies than others. To
facilitate the isolation of additional substrate sequences, 12 most-
abundant sequences were removed by hybridizing the selected pool
with 18 biotinylated oligonucleotides complementary to the short-
est overlapping regions of each abundant sequence (SI Tables 5 and
6), followed by passage through a streptavidin-agarose column. It
was found that such subtraction was very efficient, and the abun-
dance of these sequences was significantly reduced by only one such
subtraction (SI Table 5). After this treatment, a large number of
previously uncharacterized caspase-3 substrates, which otherwise
might be difficult to detect, were successfully identified.
Efficient Proteolytic Analysis of Selected Sequences. The cleavage of
each selected protein fragment by caspase-3 was tested by an in vitro
proteolytic assay, using radiolabeled protein generated by coupled
in vitro transcription and translation (TNT), in the presence or
absence of a caspase-3 inhibitor (Ac-DEVD-CHO). Each reaction
mixture was loaded to a high resolution Tricine-SDS/PAGE for
analysis. Numerous positive and negative controls were tested to
confirm that this in vitro proteolytic assay is robust, provided that
the protein of interest is translated well in rabbit reticulocyte lysate
(data not shown). As illustrated in Fig. 2 using six selected proteins
as examples, the cleavage of positive sequences was observed when
purified caspase-3 was present, but totally abolished when caspase-3
was preinhibited by a specific inhibitor. Among 207 unique proteins
from a total of 580 clones we picked up for analysis, 173 were
translated well by TNT, among which 115 proteins (66%) were
found to be specifically cleaved by caspase-3. These 115 caspase
substrates are listed in Table 1 and SI Table 2 for new and previously
characterized caspase-3 substrates, respectively. Most of the se-
lected sequences contain 80 to 200 aa residues from the corre-
sponding ORFs. A typical selected sequence is shown in Supple-
mental Fig. 3. Blast analysis indicates that this is a fragment
(Gln32-Gly154) from the N terminus of protein kinase C-like 2
(PKN2, full-length 984-residue), a caspase-3 substrate previously
identified using the small pool expression cloning strategy (3).
Among these 115 positive sequences, 26 were fragments from
previously reported caspase-3 substrates (SI Tables 2 and 3). Unlike
other methods that result in the enrichment of certain classes of
proteins (14), the caspase-3 substrates selected here include regu-
latory proteins involved in various signaling pathways and are not
limited to any particular class.
We were not able to identify all of the caspase-3 substrates
reported in the literature. However, the absence of those known
caspase-3 substrates from our list does not necessarily mean they
were not selected, because rare sequences are less likely to be picked
up for follow-up studies. We hypothesized that short fragments
surrounding the cleavage sites should be present, if these proteins
were enriched in the selection. We examined 18 known caspase-3
substrates that were not found from the clones we randomly picked
up for analysis. The presence of these genes in the selected pool was
detected by PCR amplification using gene-specific primers that
Fig. 1. Selectionschemeofcaspase substratesusinganmRNA-displayedhuman
proteome domain library. mRNA, green; DNA, red; protein, yellow; puromycin,
blue circle labeled as P; biotin, red triangle; streptavidin, blue cross; agarose
beads, solid black circle; caspase, red scissors.
Fig. 2. In vitro proteolytic cleavage of several protein fragments isolated from
round 3 selection using caspase-3. Radiolabeled protein fragments were synthe-
sized by TNT. The cleavage was carried out using 0.1 unit/l purified caspase-3 at
37°C for 2 h. In the inhibition assay, caspase-3 was preinhibited by 0.5 M
Ac-DEVD-CHO for 15 min before being used to digest TNT products. Different
proteins were not aligned according to their molecular weights. 1 is a positive
control fragment originated from a cleavage site containing sequence of PARP-1.
2–6 are fragments from nos. 4, 5, 27, 35, and 47, as listed in SI Table 4. 7 is a
negative control sequence randomly picked up from round 0. This sequence was
digested with increased amount of caspase-3 to demonstrate that its noncleav-
age nature was not changed by using 10-fold higher caspase.








target short fragments surrounding the reported caspase-3 cleavage
sites. 12 of 18 such substrates were greatly enriched in the selected
pool, as they could be amplified to the same levels as the controls
by at least 12 fewer PCR cycles. Because such PCR detection
approach is only limited to known caspase substrates whose cleav-
age sites had been characterized, we focused our efforts on studying
previously uncharacterized caspase-3 substrates.
Mapping of the Potential Cleavage Sites on the Selected Substrates.
The ease of mapping potential cleavage sites is one of the biggest
advantages of this method. As shown in SI Tables 2 and 3, almost
all of the selected fragments from the known caspase-3 substrates
contain the previously reported cleavage site(s) (4), clearly indi-
cating that our method allows efficient identification of caspase
substrates on a proteome-wide scale. Our results also allow us to
assign putative cleavage sites to these known caspase-3 substrates
whose cleavage sites have not yet been characterized. One such
example is RANBP2, a nucleoporin that was recently found to act
as an E3 ligase by binding both SUMO and Ubc9 to position the
SUMO-E2-thioester in an optimal orientation to enhance conju-
gation (15). By analyzing the fragments we isolated from RANBP2,
it was found that potential cleavage sites could be located at
DVTD111/G, DFAD2411/G, or DVAD2430/S. These cleavages will
remove the tetratricopeptide repeat (TPR) domain (one TPR,
residues 60–93) from the N terminus if the cleavage occurs at D111
or truncate the C-terminal cyclophilin ABH-like domain if the











51 MORF15 145–292/362 1–362 N
52 MPP8 432–513/860
53 MYO18A 1943–2047/2054
54 NAPLl3 97–181/506 1–506 Y
55 NDUFS1 240–328/727 1–727 Y
56 NEB 832–928/6669 550–1058 Y
57 NEXN 309–355/505 1–505 Y
58 NUCB2 175–269/420 1–420 Y
59 PCF11 319–442/1555 1–713 Y
60 PDZGEF1 329–439/1499 130–950 Y
61 PHACTR2 511–592/634 1–634 Y
62 PHTF2 267–365/785
63 PIK3R1 501–631/724
64 PIK3R3 64–215/461 1–461 Y
65 PJA2 131–237/708 1–708 Y
66 PPP1R12A 833–916/1030
67 PSIP2 69–148/530 1–530 Y
68 PSMC1 251–323/440 1–440
69 PSMC3 269–348/439 1–439
70 PSRC2 317–395/1989
71 RNF6 128–227/685 1–685 Y
72 S100PBP 85–188/408
73 SALL1 97–134/1324
74 SCG3 78–138/468 1–468 Y
75 SERBP1 180–256/402
76 SHOC2 191–308/582 1–582 Y
77 SLC4A1AP 711–782/796 1–796 Y
78 SMARCA1 856–923/1054
79 SMC5 807–910/1101
80 SORBS1 389–525/816 1–816 Y
81 SPARCL1 257–335/664 1–664 Y
82 SSFA2 439–534/1256
83 SRP54 358–436/504 1–504 Y
84 STAC3 259–363/364 1–364 N
85 SYTL2 686–797/1256
86 TAF15 99–171/589
87 TFG 23–145/400 1–400 Y
88 UTP11L 109–196/253 1–253 N
89 UTP14C 305–395/766 1–766 Y
Only selected fragments whose specific cleavage by caspase-3 has been
confirmed by SDS/PAGE are listed. Column 3 shows the range of the shortest
overlap region (SOR) and the size of the full-length protein. Column 4 shows
the range of the TNT-generated full length (FL) or of large fragment (LF) that
had been tested in caspase-3 cleavage reaction (the results are listed in column
5). The GenBank accession numbers of these proteins are listed in SI Table 4.
Y, yes; N, no. Bold text represents full-length proteins that were specifically
cleaved by caspase-3, whereas italicized text represents large fragments from
very large proteins that were specifically cleaved by caspase-3.
*Motif Scan (http://myhits.isb-sib.ch/cgi-bin/motif_scan) and Protein Blast were
usedforthepredictionofdomains,motifs,andpatterns.TheHierarchicalNeural
Network method (http://npsa-pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page
npsa_nn.html) was used for the prediction of secondary structures.
Table 1. Previously uncharacterized caspase-3 substrates isolated












3 AGGF1 504–592/714 442–714 Y
4 ALS2C13 120–223/345




9 BCAS1 244–301/584 1–584 Y
10 BNIP2 4–79/314 1–314 Y
11 BTAF1 124–241/1849 1–472 Y
12 BRWD3 1588–1641/1802 688–1384 Y
13 C10ORF6 336–446/1173
14 C12ORF11 585–696/706
15 C219 599–711/1907 493–974 Y
16 CCDC47 79–192/483 1–483 Y
17 CDC10 92–240/417 1–417 N
18 CEP1 1333–1438/2325
19 CGNL1 630–725/1302 446–912 Y
20 CHD3 602–696/1966
21 CLU 116–213/501 53–501 Y
22 COG5 450–575/839
23 DGKB 354–453/773




27 EEF1B2 59–168/225 1–225 N
28 EPRS 921–1022/1512 693–1315 N




33 GAPVD1 1051–1163/1487 940–1487 Y
34 GOLGA4 681–819/2230
35 GOLGB1 1833–1978/3259 1095–1701 Y
36 HSPA4 640–784/840 1–840 N
37 HYPB 781–900/2061 688–1263 Y
38 INO80 1322–1391/1556 1207–1556 Y
39 KIF21A 558–655/1661
40 JARID1A 1589–1685/1690 1131–1690 Y
41 KIAA0423 871–974/1720 593–1180 Y
42 KIAA0864 159–263/1402
43 KIDIN220 221–301/1771 1–627 Y
44 LMO7 1085–1184/1349 553–1271 Y
45 LOC22998 684–803/1083





49 MLL3 810–910/4025 560–1126 Y
50 MNAB 1033-1113/1191 652-1191 Y
14296  www.pnas.orgcgidoi10.1073pnas.0702251104 Ju et al.
RANBP2 in 293 cells because of its very large size. Nevertheless,
our result suggests that the functions of RANBP2 could be regu-
lated by caspase-3 during apoptosis through cleavage of these
domains. Of the fragments selected from 89 previously uncharac-
terized caspase-3 substrates whose cleavage was individually con-
firmed by in vitro proteolytic assay, most contain only one potential
DXXD cleavage site (SI Table 4). The potential caspase-3 cleavage
on such fragments most likely occurs on these residues. For the few
selected fragments that contain more than one potential caspase-3
cleavage site, we narrowed down the cleavage site(s) by mapping the
shortest overlapping region. This is possible, because a number of
sequences were isolated as multiple fragments of different lengths
derived from the same parental ORF. For example, by aligning
three PKN2 fragments isolated from the selection, the shortest
overlapping region was found to be between residues 65–140, which
covers only DEPDITD117/C but not the other two potential cleav-
age sites (SI Fig. 8). This DEPDITD117/C cleavage site was further
confirmed by analyzing the sizes of the proteolytic products using
high resolution Tricine-SDS/PAGE (data not shown). Indeed, the
in vitro cleavage site thus identified is identical to that mapped under
physiological conditions (3). However, it is still possible that in some
cases more than one potential cleavage site is present in the shortest
overlapping region, as in secretogranin III (SCG3), an acidic
secretory granin protein that is specifically expressed in neuronal
and endocrine cells. All of the isolated protein fragments originat-
ing from SCG3 contain a common region from residues Leu78 to
Leu138, which includes the two potential cleavage sites DDYD121/S
and DDPD136/G. In vitro proteolytic analysis using in vitro-
translated fragment and full-length SCG3 showed that the cleavage
sites were indeed within this common region. Because these two
potential cleavage sites are very close to each other, it is difficult to
unambiguously determine which one is cleaved using Tricine-SDS/
PAGE. Nevertheless, this approach allows us to effectively narrow
down the potential cleavage site(s) to a region of 20 residues.
Proteolytic Analysis of Full-Length Proteins. We further investigated
the caspase-3-mediated cleavage of those proteins whose full-length
form could be expressed well using the TNT system. Of 33 such
full-length proteins from the 115 that were shown to be cleavable
as fragments, 26 (79%) were specifically cleaved by caspase-3
(Table 1, column 4, bolded). Interestingly, a number of the selected
fragments were from very large proteins with 1,000 aa that we
could not express as full-length proteins. For these proteins, we
generated large fragments of 500–800 aa that cover the selected
sequences and used these large fragments to test cleavage by
caspase-3. The boundaries of these fragments were chosen on the
basis of online domain prediction algorithms Motif Scan and
Hierarchical Neural Network (Table 1 and SI Table 4). Interest-
ingly, 19 of 20 such selected sequence-containing large fragments
were cleaved by caspase-3 (Table 1, column 4, italicized). The sizes
of the observed cleavage fragments on SDS/PAGE were consistent
with those predicted based on the mapped cleavage sites. These
results demonstrate that although the caspase-3 cleavable se-
quences isolated from the selection were relatively short (80–200
residues), most of the corresponding full-length or large fragments
were indeed cleaved by caspase-3.
Caspase Specificity of Selected Substrates. Because of the presence
of multiple caspases in eukaryotic cells, it is of great importance to
determine which member of the caspase family is responsible for
the observed cleavage. To address this issue, we investigated the
cleavage specificity of several potential previously uncharacterized
caspase-3 substrates with 10 human caspase members (Fig. 3).
These full-length proteins were either overexpressed in HEK 293T
(Fig. 3A) or generated by TNT in rabbit reticulocyte lysate (Fig. 3B).
We found that affinity-tagged overexpressed proteins listed in Fig.
3A were cleaved during apoptosis, but the cleavage was not blocked
by caspase inhibitors, possibly because they were also cleaved by
other enzymes that were present in cells. Therefore, we added
purified caspase family members to uninduced cell lysates to
investigate whether the overexpressed proteins in mammalian cells
were indeed cleaved by caspases (Fig. 3A). Consistent with the
conditions applied in the selection, all of these proteins could be
efficiently cleaved by caspase-3 but not by caspase-3 preincubated
with a specific tetrapeptide inhibitor. The cleavages were all time-
dependent, as shown in SI Fig. 9 or PIK3R3 as an example.
Interestingly, most of these proteins were also digested by caspase-6
and/or -7. The cleavage patterns are very similar to that by caspase-3
but could be different as shown in ESRRBL1 (Fig. 3B). This is
presumably because caspases-3, -6, and -7 belong to the same family
of executioner caspases and therefore have similar specificities.
However, the extent and/or pattern of cleavage by other executioner
caspases (-6 and -7) could be different, suggesting they have
different cleavage efficiencies or recognition sites. Interestingly,
several substrates were also cleaved by caspase-8 with similar
cleavage patterns. This result indicates that caspase-3 and -8 share
some common substrates, although they have different cleavage
specificities.
Substrates Cleaved Only by Caspase-8 Could Be Readily Selected. To
demonstrate that our method is not limited to caspase-3 but can be
generally used to identify downstream substrates of other members
of caspase, we performed another proteome-wide selection using
caspase-8. We then studied the cleavage of the proteins isolated
from the caspase-8 selection by either caspase-3 or -8. More than
30 proteins were found to be cleaved by caspase-8 (unpublished
data). Many of the selected caspase-8 substrates could also be
cleaved by caspase-3, presumably because some caspase-8 cleavage
Fig. 3. Caspase cleavage specificity of full-length pro-
teins. (A) Ex vivo proteolytic cleavage of several full-
length proteins by different human caspase members.
The V5/His-tagged full-length proteins were overex-
pressed in HEK 293T cells. The cleavage was carried out
using 0.1 unit/l various purified caspases at 37°C for 6 h
with an appropriate amount of cell lysate. The proteins
were detected by Western blotting using anti-V5 anti-
body. In the inhibition assay of caspase-3, caspase-3 in-
hibitor Ac-DEVD-CHO was used at 10 M. (B) Specificity
of in vitro proteolytic cleavage of several radiolabeled
full-length proteins generated by TNT. The cleavage was
carried out by using 0.1 unit/l of various purified
caspases at 37°C for 3 h. The full names and the clone
numbers of the proteins are listed in SI Table 4. The clone
numbers of the proteins shown are: CCDC47 (no. 16),
SLC4A1AP (no. 77), M11S1 (no. 46), PHACTR2 (no. 61),
SPARCL1 (no. 81), PIK3R3 (no. 64), and ESRRBL1 (no. 29).








sites are recognized by caspase-3. Significantly, a number of these
selected caspase-8 substrates were specifically cleaved by caspase-8
but not by caspase-3 (Fig. 4A). These results clearly demonstrate
that the mRNA display-based proteolytic selection can be used to
decipher family member-specific substrates for each caspase in the
caspase family.
Caspase-3 and Granzyme-B Substrates Could Be Readily Distinguished.
We also used this method to study the substrates of granzymes, a
class of specific proteases that play central roles in cytotoxic
lymphocyte-mediated apoptosis. Like caspases, granzyme B is a
specific protease with a stringent preference of an aspartic residue
at the P1 position and therefore shares many substrates with
caspases (8, 16, 17). To understand the apoptotic signaling pathways
specifically mediated by granzyme B, it is of great importance to
identify the substrates that are only cleaved by granzyme-B but not
by caspases. It was reported that residues outside the P4-P2 motif
also contribute to the substrate recognition and binding by gran-
zyme B, making the identification of granzyme B-specific substrates
more challenging than that of caspases. We attempted to enrich
such specific substrates of granzyme B by preremoval of sequences
cleavable by caspases through incubating an immobilized, mRNA-
displayed human proteome domain library with a mixture of
caspases (caspases-2, -3, -6, -7, -8, -9, and -10) before selecting
sequences that can be released by purified granzyme B. More than
60 granzyme B-substrates were successfully identified (unpublished
data). Fig. 4B shows a few such examples. Only a few of the selected
sequences, such as SERBP1, were still cleaved by caspases, but
usually with different cleavage patterns. This preremoval of se-
quences that are recognized by other proteases can be widely used
in such mRNA display-based method to identify substrates that are
cleaved only by a protease of interest.
Cleavage of the Selected Substrates Under in Vivo Conditions. We also
investigated whether the cleavage of several selected caspase sub-
strates indeed occurs during apoptosis when the proteins are
present at their endogenous concentrations. The in vivo cleavage of
the known caspase-3 substrates listed in SI Table 2 has been
reported by numerous studies (4). Because most previously un-
characterized substrates of interest do not have commercially
available antibodies, it is difficult to investigate them in vivo when
the proteins of interest are present at their endogenous concentra-
tions. We first demonstrated that the cleavage of endogenous
SRP54 and EIF4B were observed in vivo under apoptotic condi-
tions (SI Fig. 10). We then examined the cleavage of fragile X
mental retardation syndrome-related protein 2 (FXR2), a caspase
substrate identified from the selection using caspase-8 rather than
caspase-3. FXR2 is similar to FMRP and FXR1, both of which are
involved in RNA binding, polyribosomal association, and nucleo-
cytoplasmic shuttling (18). These genes have been implicated in the
development of fragile X mental retardation syndrome. The short-
est overlapping region on FXR2 recognized by caspase-8 was found
to be between Leu564-Ser634, and the potential cleavage site was
mapped at LESD567/G (SI Fig. 11). Interestingly, this cleavage site
is just 13 residues upstream of the functional nucleolar-targeting
signal (Arg581-Arg594), which is involved in mediating the intranu-
clear distribution of FXR2 and some FXR1 isoforms (18). We
found that full-length FRX2 was specifically cleaved by caspase-8,
but not by caspase-3, when digested using purified caspase-3 or -8,
respectively (Fig. 5A). The sizes of the proteolytic products were
consistent with a caspase-8 cleavage site at D567/G. Its in vivo
cleavage under apoptotic conditions was also observed, although it
is less clear whether the cleavage is mediated by only one caspase
(Fig. 5B). It appears that the large fragment was further digested by
other caspases or proteases in vivo. Our results suggest that the
C-terminal nucleolar-targeting signal of FXR2 is removed by
Fig. 5. Ex vivo and in vivo cleavage of FXR2 during
CPT-mediated apoptosis. (A) Western blotting analysis of
ex vivo cleavage of FXR2 by caspase-3 or -8. Caspase-8 or -3
(0.1 unit/l) was added to HeLa S3 or MCF-7 whole-cell
lysates for 6 h at 37°C, in the presence or absence of Ac-
IETD-CHO at 5 M. The treated lysate was separated on
SDS/PAGE gels and probed with anti-FXR2. The ex vivo
cleavage of PARP1 was monitored as a positive control. (B)
Western blotting analysis of the in vivo cleavage of FXR2
during apoptosis in HeLa S3 cells induced by CPT. Cells were
treated with 2 M CPT for 12 h. For the FRX2 cleavage
inhibition assay, cells were pretreated with a caspase in-
hibitorat50 Mfor3hbefore theadditionofCPT.Theblot
membranes were probed with anti-FXR2.
Fig. 4. Proteolytic cleavage of fragments from caspase-8
and granzyme B selections. (A) In vitro proteolytic cleavage
of several protein fragments isolated from round 5 selection
using caspase-8. Radiolabeled protein fragments were syn-
thesized by TNT. The cleavage was carried out by using 0.1
unit/l of purified caspase-3 or -8 at 37°C for 6 h. In the
inhibition assay of caspase-8, caspase-8 inhibitor Ac-IETD-
CHO was used at 5 M. The proteins are: 1, PJA2; 2, ZCWPW2;
3, POLR3GL; 4, NRG1; 5, FLJ21352; 6, KIAA0701; 7, EEA1; and
8, FXR2. (B) In vitro proteolytic cleavage of several protein
fragments isolated from round 2 selection using granzyme B.
Radiolabeled protein fragments were synthesized by TNT.
The cleavage was carried out by using 0.1 unit/l of purified
caspase-3 or 0.2 unit/l granzyme B at 37°C for 6 h. The
proteins are: 1, SERBP1; 2, KBTBD10; 3, C11ORF58; and 4,
FILIP1L. The full names of these proteins are given in SI
Table 6.
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caspase during apoptosis, thus effectively preventing its localization
in nucleolus and disrupting most of its functions.
Limitations and Advantages of the Method. Although mRNA display
is a powerful method that allows for efficient identification of
caspase family member-specific substrates, this method does have
its limitations. The efficiency with which a particular sequence is
selected depends on several factors, including its mRNA abundance
and the efficiencies of protein expression and caspase-catalyzed
cleavage. This might explain why only a fraction of known caspase-3
substrates were identified. However, because we were not able to
exhaustively analyze the selected pool, more known substrates
could be identified by analyzing more colonies. In addition, the
substrates reported here were identified and characterized by in
vitro approaches using purified caspases. Whether a specific protein
is cleaved during apoptosis under physiological conditions requires
individual examination. Therefore, this method is complementary
to previously used methodologies. Nevertheless, this method is thus
far the most broadly applicable strategy for the identification of a
large number of diverse caspase substrates. The in vitro nature of
this method allows us not only to attribute the cleavages to a specific
caspase member but also to efficiently remove the abundant or
biased sequences. The method reported here is systematic and high
throughput and can be broadly applied to all members of human
caspases, caspases in other organisms, and numerous other pro-
teases with high specificity. Therefore, the natural substrate rep-
ertoire of caspases in other organisms, including CED-3, DRONC,
and DrICE from Caenorhabditis elegans and Drosophila, respec-
tively, should be readily identifiable using the same approach. The
availability of this information will greatly facilitate our understand-
ing of apoptotic signaling pathways.
Materials and Methods
Generation of the mRNA-Displayed Proteome Domain Library and
Site-Specific Biotinylation of the N Termini of the Protein Sequences.
The library was constructed as detailed in SI Text. A sequence
coding an AviTag was introduced at the very N terminus of the
ORF (13). mRNA-protein fusions were generated and purified
from the lysate, as described (12), followed by incubation with an
appropriate amount of BirA (Avidity, Denver, CO) in a biotinyla-
tion buffer at 30°C for 4 h for site-specific in vitro biotinylation. After
reverse transcription to convert the fusion molecules to DNA/RNA
hybrids, the mRNA-displayed proteome domain library was puri-
fied on the basis of the affinity tags.
Selection of Caspase Substrates from mRNA-Displayed Human Pro-
teome Domain Library. The purified proteome domain library (1.5
pmol each round) was first diluted in a caspase reaction buffer with
10 mM DTT and 1 mM EDTA and passed through a precolumn
of 100 l of streptavidin-agarose beads preblocked with excess
amount of biotin. The flowthrough was then incubated with the
same amount of streptavidin-agarose beads for 1 h at room
temperature. Unbound and nonspecifically bound molecules were
washed off the column using 250 column volumes of reaction
buffer. To further remove sequences that might be nonproteolyti-
cally released, we carried out a preincubation under the otherwise
same reaction conditions, except BSA was used to replace the
caspase of interest. The immobilized proteome domain library was
then incubated with appropriate amount of purified caspase (Bio-
Vision, Mountain View, CA) in 300 l of reaction mixture at 37°C
for 1.5 h with rotation. Proteins specifically cleaved by the caspase
of interest were released from the solid surface. The selected
molecules were PCR-amplified for the next round of selection or
cloned into a TOPO vector for sequencing and analysis.
In Vitro Proteolytic Analysis of Selected Substrates. Individually
cloned sequences isolated from the selection were PCR-amplified
using two consensus primers. Full-length genes of interest were
RT-PCR-amplified using gene-specific primers from a human
cDNA library. Purified PCR products were used as templates for
TNT in the presence of 10 Ci (1 Ci  37 GBq) [35S]methionine
in a total volume of 12.5 l for 90 min at 30°C. To perform in vitro
proteolytic analysis, an aliquot of each translation reaction mixture
was incubated in a reaction buffer at 37°C for 2–6 h with an
appropriate amount of active caspase or caspase preinhibited by a
tetrapeptide inhibitor. An aliquot of each reaction mixture was
loaded onto an SDS/PAGE gel for separation and signal detection.
Ex Vivo Cleavage Assay. Caspase-catalyzed proteolysis of overex-
pressed proteins was performed by the addition of an appropriate
amount of exogenous caspase to HEK 293T whole-cell extracts.
Each digestion reaction contains 0.2–2 units of caspase and 25–50
g of total protein from cell lysate. The reaction mixture was
incubated at 37°C for various times. Similarly, cleavage analysis of
endogenous FXR2 was accomplished by adding caspase-8 or -3 to
the cleared untreated HeLa S3 or MCF-7 lysates. Inhibition reac-
tions were performed by preincubating 5 M caspase-3 (Ac-
DEVD-CHO) or caspase-8 (Ac-IETD-CHO) inhibitor with the
corresponding caspase for 30 min at 37°C. Afterward, 25–50 g of
cell lysate was added and incubated for an additional 6 h at 37°C.
Proteins in lysates were resolved by SDS/PAGE, and blots were
probed with anti-V5 (Invitrogen), anti-FXR2 (Abcam, Cambridge,
MA), or anti-PARP1 (Upstate Biotechnology, Billerica, MA) as a
positive control.
In Vivo Cleavage Assay. For caspase-catalyzed in vivo cleavage of
BID, EIF4B, SRP54, and FXR2, 2 M camptothecin (CPT)
(Calbiochem, San Diego, CA) was directly added to growing HeLa
S3 to induce apoptosis. For cleavage inhibition assay, cells were
pretreated with 50 M of a particular caspase inhibitor for 3 h at
37°C, before induction of apoptosis by CPT. Approximately 25–50
g of cell lysate was loaded into each well, separated by SDS/PAGE.
Blots were probed with various antibodies including anti-BID
(BioVision), anti-EIF4B (Cell Signaling Technology, Danvers,
MA), anti-SRP54 (BD Biosciences, San Jose, CA), anti-FXR2, and
anti- actin (Sigma, St. Louis, MO).
For further information, see SI Figs. 6–11 and Tables 2–6.
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